Education
Executive education in business development and commercial leadership.
Experience and prior assignments
More than 20 years of experience from the pharmaceutical, biotech and MedTech industries, where he has held several senior commercial leadership roles and executive positions, with responsibility for commercial strategy, business development and organisational development in Nordic and international markets.
Prior to joining Dizlin Pharmaceuticals, he spent several years in leading roles within commercial services and advisory, supporting life science companies in both established and growth phases with market entry, launch preparation and commercial execution.
Education
Executive MBA from Lund University, Sweden
Experience and prior assignments
More than 35 years of experience from the pharmaceutical industry, whereof 25 years at Lundbeck A/S, where he has held several international leading roles and executive positions: Sales and Marketing Director for Sweden, Managing Director for The Netherlands and Managing Director Sweden. Prior to joining Dizlin Pharmaceuticals, he spent four years abroad as President for Lundbeck, Japan.
Education
Medical Doctor and Professor of Pharmacology at the Department of Physiology and Neuroscience, Sahlgrenska Academy, University of Gothenburg, Sweden
Other assignments
Board member at Dizlin Pharmaceuticals AB since 2018
Experience and prior assignments
Active in preclinical and clinical neuropsychopharmacological research for four decades, written approximately 300 scientific papers within these fields, and supervised 20 PhD students. Has been a member of the Scientific Council for Medicine and Health at the Swedish Research Council and is currently a Board member and the Secretary of the International College of Neuropsychopharmacology (CINP).
Education
PhD, M Pharm Sci, Associate Professor, Faculty of Pharmacy, University of Uppsala, Sweden
Other assignments
Senior Adviser in Drug Development and Chairman of the Board at Pharm Assist Sweden AB
Experience and prior assignments
More than 45 years of experience from the life science, pharmaceutical and medical device industries. During several years, he been a board member and secretary of the Swedish Society for Clinical Studies. Since 1980, he has been working as a consultant in his own Contract Research Organisation (CRO), and later on as Head of Nordic Regulatory Affairs and Clinical Trials for an international CRO. In 1996, he started Pharm Assist Sweden AB. In 2014, he joined the Infudopa project at Dizlin Pharmaceuticals AB. He is together with Elias Eriksson, Nil Dizdar and Leif Bring inventor of the infusion solution Infudopa™.
Education
Dr of Naprapathy, University of Chicago (Swe. leg. Naprapat)
Courses in Marketing Management
Experience and prior assignments
More than 25 years of experience from sales, marketing, and management positions in both pharmaceutical and medical device industry. As a leader his strength and focus are on development, growth, and progress. He has worked in small and large organizations in Sweden as well as internationally. His previous international experience has been in the areas of product launches and market expansions.
Education
MSc Pharm, PhD
Other assignments
CEO of RegSmart Life Science AB
Experience and prior assignments
More than 25 years of experience from regulatory in drug development. As Director at the Swedish MPA, she was responsible for drug approvals including scientific advice and clinical trials. As regulator, she has actively contributed to development of new guidelines and legislation. She has worked in big- and small pharma developing global regulatory strategies for several compounds from early development up to market approval. She has led due diligence activities and scientific advice meetings in EU and the US.
Education
BS, Economics, State University of New York College at Plattsburgh, USA
Experience and prior assignments
More than 25 years of experience in finance, asset management and the life science sector, with senior leadership roles across Ireland, the US and Sweden.
Prior to joining Dizlin Pharmaceuticals, Daniel held the position of CFO at Infant Bacterial Therapeutics AB, where he was part of the team that successfully completed a capital raise of SEK 545 million and managed the company’s uplisting to NASDAQ Stockholm MidCap. He concurrently serves as Chief Operating Officer at Protean Funds Scandinavia AB.